But increasingly now the research community has been investigating the dark side of reductase inhibitors, touted for years as "So free of side effects they should be put into the drinking water."
Recently Wahl D and others of the Dept. of Vascular Medicine, Nancy, France reported in Elsevier on the mechanisms of statin associated myopathy, defining lack of availability of CoQ10 as playing an important causative role. They also demonstrated the benefit of supplemental CoQ10 both in the prevention and treatment of statin myopathy.
The loss of anti-oxidation capacity secondary to CoQ10 lack deserves far more study. Our mitochondria are front line warriors in the sense of having to work directly in the toxicity of a high oxygen environment. Without sufficient anti-oxidation, somatic mutations can rapidly damage the energy producing capacity of our mitochondria. They are extremely vulnerable to oxidation.
It is safe to say that the biochemists of all drug companies are fully aware of the problems to come from reductase inhibition of the mevalonate pathway. They better than anyone have been well aware that CoQ10, dolichols, selenoproteins and tau proteins are inevitably affected by statins in today's high doses but their management has chosen to ignore this. Unfortunately for them the problem has not gone away. It has increased tragically as statin sales have sky-rocketed.
Duane Graveline MD MPH
Former USAF Flight Surgeon
Former NASA Astronaut
Retired Family Doctor